Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Electrocardiogram Monitoring Wearable Devices and Artificial-Intelligence-Enabled Diagnostic Capabilities: A Review.

Sensors (Basel, Switzerland)·2023

Same author

Diagnostic and Prognostic Role of CD93 in Cardiovascular Disease: A Systematic Review.

Biomolecules·2023

Same author

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).

Journal of hypertension·2023

Same author

Lung ultrasound in the COVID-19 era: a lesson to be learned for the future.

Internal and emergency medicine·2023

Same author

Serum uric acid to creatinine ratio and risk of preeclampsia and adverse pregnancy outcomes.

Journal of hypertension·2023

Same author

Is the First Cut Always the Deepest?

Hypertension (Dallas, Tex. : 1979)·2023

Search research articles

Related Experiment Videos

Lercanidipine in hypertension.

Claudio Borghi¹

¹Dipartimento di Medicina Clinica e Biotecnologia Applicata D Campanacci, Università degli Studi di Bologna, Bologna, Italy. claudio.borghi@unibo.it

Vascular Health and Risk Management

|February 27, 2007

Summary

Lercanidipine, a dihydropyridine calcium antagonist, effectively lowers blood pressure with once-daily dosing and is well-tolerated. It shows a lower incidence of side effects like pedal edema compared to other agents, making it a suitable hypertension treatment.

Area of Science:

Pharmacology
Cardiovascular Medicine

Background:

Lercanidipine is a lipophilic dihydropyridine calcium antagonist.
It possesses a long receptor half-life and a slow onset of action, mitigating reflex tachycardia common with other dihydropyridines (DHPs).

Purpose of the Study:

To evaluate the efficacy and tolerability of lercanidipine in hypertension management.
To compare its adverse effect profile, particularly pedal edema, with other antihypertensive agents.

Main Methods:

The study assessed lercanidipine's antihypertensive efficacy and tolerability.
Comparative analysis included incidence of adverse effects like pedal edema versus amlodipine and nifedipine gastrointestinal transport system.

Main Results:

Lercanidipine provides sustained blood pressure lowering with once-daily dosing, demonstrating efficacy in diverse patient groups.

Related Experiment Videos

It is well-tolerated, with DHP-associated adverse effects occurring early and a lower incidence of pedal edema compared to amlodipine or nifedipine.

Preliminary findings suggest potential benefits for atherosclerosis and left ventricular hypertrophy.

Conclusions:

Lercanidipine exhibits favorable efficacy and tolerability profiles for hypertension treatment.
Its characteristics make it a suitable option for a broad range of hypertensive patients, including those with risk factors.